With multiple FDA drug approval decisions on the horizon — including one expected later today — Biogen Inc. CEO Christopher Viehbacher isn't waiting to maximize profits.
In its first-quarter earnings release Tuesday morning, the Cambridge drugmaker disclosed that it had stopped development on a handful of experimental drugs. Among them are one for ischemic stroke and brain bruising that it had been developing with Remedy Pharmaceuticals, plus another for ischemic stroke and a third drug for spinocerebellar ataxia, a group of inherited brain disorders.
STAY IN THE KNOW
 |
Watch NBC10 Boston news for free, 24/7, wherever you are. |
 |
Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters. |
More on this story from Boston Business Journal
Get top local stories in Boston delivered to you every morning. Sign up for NBC Boston's News Headlines newsletter.
